Novel strategies for pharmacotherapy of depression

Current Opinion in Chemical Biology

Volumn 3, Issue 4, 1999, Pages 481-488

  Maubach, Karen A ^a   Rupniak, Nadia M J ^a   Kramer, Mark S ^b   Hill, Raymond G ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; APREPITANT; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP; IMIPRAMINE; MIRTAZAPINE; MONOAMINE; NEUROPEPTIDE; NORADRENALIN; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; SUBSTANCE P ANTAGONIST; UNCLASSIFIED DRUG; VENLAFAXINE;

DEPRESSION; HUMAN; REVIEW; SECOND MESSENGER;

EID: 0033179364     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(99)80070-2     Document Type: Article

References (65)

1. Bernadt M: Drug treatment of depression. Semin Gen Adult Psych 1998, 1/2:154-219.
2. Healy D: The Antidepressant Era. Cambridge, MA: Harvard University Press; 1997.
3. Finley PR: Selective serotonin re-uptake inhibitors: Pharmacological profiles and potential therapeutic distinctions. Ann Pharmacother 1994, 28:1359-1369.
4. Preskorn SH, Janicak PG, Davis JM, Ayd FJ: Advances in the pharmacotherapy of depressive disorders. In Principles and Practice of Psychopharmacotherapy. Edited by Janicak PG. New York: Williams and Wilkins; 1995.
5. Norman TR, Leonard BE: Fast-acting antidepressants: Can the need be met? Cen Nerv Syst Drugs 1994, 2:120-131.
6. Kuhn R: The treatment of depressive states with G-22355 (imipramine hydrochloride). Am J Psychiatry 1958, 111:459-464.
7. Richelson E: Pharmacology of antidepressants - Characteristics of the ideal drug. Mayo Clin Proc 1994, 69:1069-1081.
8. Joffe RT, Marshall AM, Lee DK: A large open-label study of venlafaxine in depressed outpatients by community-based physicians. J Clin Psychiatry 1998, 59:515-520.
9. Rudolph RL, Entsuah R, Chitra R: A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol 1998, 18:136-144.
10. Samuelian JC, Hackett D: A randomized, double-blind, parallel group comparison of venlafaxine and clomipramine in outpatients with major depression. J Psychopharmacol 1998, 12:273-278. The safety and efficacy of serotonin/noradrenaline re-uptake inhibitor (SNRI), venlafaxine was compared with the tricyclic antidepressant (TCA) clomipramine (50-150 mg/day) in 102 outpatients with major depression. Both drugs produced similar decreases in two depression rating scales (Montgomery Asberg and Hamilton). However, significantly more patients in the clomipramine-treatment group reported adverse-effects (anticholinergic) than in the venlafaxine-treatment group. Therefore this SNRI has a better adverse-effect profile than the TCA, but there is no clinical evidence to suggest a greater efficacy or profile than the serotonin re-uptake inhibitors.
11. Kasper S, Pletan Y, Solles A, Tournoux A: Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: A summary of clinical trial results. Int Clin Psychopharmacol 1996, 11:35-39.
12. Guelfi JD, Ansseau M, Corruble E, Samuelian JC, Tonelli I, Tournoux A, Pletan Y: A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 1998,13:121-128.
13. Tignol J, Pujol-Domenech J, Chartres JP, Leger JM, Pletan Y, Tonelli I, Tournoux A, Pezous N: Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatry Scand 1998, 97:157-165. This study reported a similar efficacy for both milnacipran and imipramine; however, a lower incidence of adverse effects with milnacipran than with the tricyclic antidepressant imipramine was seen.
14. 123l]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998, 44:1090-1098.
15. Smeraldi E, Zanardi R, Benedetti F, DI Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998, 3:508-511. Smeraldi and colleagues found that a small sample of patients who are homozygous for the short form of the polymorphism, within the promoter of the serotonin transporter (HIT), which results in lower levels of HIT mRNA, have less capacity to increase synaptic serotonin by re-uptake inhibition and therefore a significantly poorer response to treatment using the serotonin reuptake inhibitor (SSRI), fluvoxamine. It is possible that allelic variation of the HIT polymorphic region and therefore expression and activity of HTT in patients may explain the different responsiveness to SSRI treatment. They further observed that this difference in treatment response disappears when fluvoxamine treatment is augmented with pindolol.
16. Charney DS: Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998, 59:11-14.
17. Nemeroff CB: Psychopharmacology of affective disorders in the 21st century. Biol Psychiatry 1998, 44:517-525.
18. 1a receptors in psychopathology and the mechanism of action of clinically effective therapeutic agents. Drug News Perspect 1996, 9:270-280.
19. Ferez V, Gilaberte I, Paries D, Alvarez E, Artigas F: Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment Lancet 1997, 349:1594-1597.
20. Dimitriou EC, Dimitriou CE: Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998, 18:465-469.
21. Landen M, Bjorling G, Agren H, Fahlen T: A randomized, double blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment refractory depression. J Clin Psychiatry 1998, 59:664-668. Adding buspirone to a serotonin re-uptake inhibitor (SSRI) is a safe and well-tolerated drug regimen; however, this study failed to demonstrate any difference in efficacy between buspirone or placebo augmentation of an SSRI.
22. Fischer P, Tauscher J, Kufferle B, Kasper S: Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin Psychpharmacol 1998, 13:83-86.
23. 1a receptor mutant mice. Proc Natl Acad Sci USA 1998, 95:15049-15054.
24. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, Mann JJ, Brunner D, Hen R: Serotonin receptor 1A knockout: An animal model of anxiety-related disorder. Proc Natl Acad Sci USA 1998, 95:14476-14481.
25. Rosen RC, Lane RM, Menza M: Effects of ssris on sexual function: A critical review. J Clin Psychopharmacol 1999, 19:67-85.
26. Davis R, Whittington X, Bryson HM: Nefazodone: A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997, 53:608-636.
27. 2a receptor antagonistic activity. Neuropharmacology 1997, 35:1621-1626.
28. Stahl SM: Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry 1998, 59:23-29.
29. Richards JB, Sabol KE, Hand TH, Jolly DC, Marek GJ, Seiden LS: Buspirone, gepirone, ipsapirone and zalospirone have distinct effects on the differential-reinforcement-of-low-rate 72-second schedule when compared with 5-HTP and diazepam. Psychopharmacology 1994, 114:39-46.
30. Borsini F, Cesana R, Kelly J, Leonard BE, McNamara M, Richards J, Seiden L: BIMT 17: A putative antidepressant with a fast onset of action? Psychopharmacology 1997, 134:378-386.
31. De Boer T: The pharmacologic profile of mirtazepine. J Clin Psychiatry 1996, 57:19-25.
32. Fawcett J, Barkin RL: A meta-analysis of eight randomised, double-blind, controlled clinical trials of mirtazepine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998, 59:123-127. Mirtazapine was found to be as effective as amitriptyline in placebo-controlled trials.
33. Caille D, Bergis OE, Fankhauser C, Gardes A, Adam R, Charieras T, Grosset A, Rovei V, Jarreau FX: Befloxatone, a new reversible and selective monoamine oxidase-a inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther 1998, 277:265-277.
34. Haddjeri N, De Montigny C, Curet O, Blier P: Effect of the reversible monoamine oxidase-a inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission. Eur J Pharmacol 1998, 343:179-192.
35. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJH, Laird JMA, Belmomte C, Cervero F, Hunt SP: Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998, 392:394-397.
36. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-Knowles E et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281:1640-1645. The first demonstration of antidepressant efficacy of the brain-penetrant substance P receptor antagonist, MK-0869.
37. Shiriyama Y, Mitsushio H, Takashima M, Ichikawa H, Takahashi K: Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat. Brain Res 1996, 739:70-78.
38. Mitchell AJ: The role of corticotropin releasing factor in depressive illness: A critical review. Neurosci Biobehav Rev 1998, 22:635-651.
39. ArboreLius L, Owens MJ, Plotsky PM, Nemeroff CB: The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999, 160:1-12. This is a review of both clinical and preclinical evidence that suggests the involvement of corticotrophin-releasing factor in depression and anxiety disorders.
40. Raadsheer FC, van Heerikhuize JJ, Lucassen PJ: Corticotropin-releasing hormone mRNA in paraventricular nucleus of patients with alzheimer's disease or depression. Am J Psychiatry 1995, 152:1372-1376.
41. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul Jmhm, Stalla GK, Blanquet V, Sleekler T, Holsboer F, Wurst W: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998, 19:162-166.
42. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley Caet al.: Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998, 20:1093-1102.
43. Aubry JM, Pozzoli G, Vale WW: Chronic treatment with amitriptyline decreases CRF-R1 receptor mRNA levels in the rat amygdala. Biol Psychiatry 1997, 42:236S.
44. Mansbach RS, Brooks EN, Chen YL: Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 1997, 323:21-26.
45. De Felipe C, De Ceballos ML, Gil C, Fuentes JA: Chronic antidepressant treatment increases enkephalin levels in the nucleus accumbens and striatum of the rat. Eur J Pharmacol 1985, 112:119-122.
46. Hummel T, Hunnel C, Friedel Y, Pauli E, Kobal GA: A comparison of the antinociceptive effects of imipramine tramadol and ampirtoline. Br J Clin Pharmacol 1994, 37:325-333.
47. Gallego M, Casis L, Casis O: Imipramine inhibits soluble enkephalin-degrading aminopeptidase activity in vitro. Eur J Pharmacol 1998, 360:113-116.
48. De Gandarias JM, Echevarria E, Acebes I, Silio M, Casis L: Effects of imipramine administration on mu-opioid receptor immunostaining in the rat forebrain. Drug Res 1998, 48:717-719.
49. De Gandarias JM, Echevarria E, Acebes I, Abecia LC, Casis O, Casis L: Effects of fluoxetine administration on mu-opioid receptor immunostaining in the rat forebrain. Brain Res 1999, 817:236-240.
50. 18f]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 1999, 45:180-186.
51. Arcaya JL, Cano G, Gomez G, Maixner W, Suarez-Roca H: Dynorphin A increases substance P release from trigeminal primary afferent C-fibers. Eur J Pharmacol 1999, 366:27-34.
52. Bodkin JA, Zornberg GL, Lukas SE, Cole JO: Buprenorphin treatment of refractory depression. J Clin Psychopharmacol 1995, 15:49-57.
53. Wolkowitz OM, Reus VI, Roberts E, Manfred! F, Chan T, Raum WJ, Ormiston S, Johnson R, Canick J, Brizendine L, Weingartner H: Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatr 1997, 41:311-318.
54. Masugi M, Yokoi M, Shigemoto R, Muguruma K, Watanabe Y, Sansig G, van der Putten H, Nakanishi S: Metabotropic glutamate receptor subtype 7 ablation causes deficit in fear response and conditioned taste aversion. J Neurosci 1999, 19:955-963.
55. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ: Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 1998, 284:651-660. Activation of group II metabotropic glutamate receptors produced benzodiazepine-like efficacy in the fear-potentiated startle and elevated plus-maze models of anxiety in rats. LY354740 produces no CNS depression and other unwanted benzodiazepine-like activities in animals.
56. Nibuya M, Nestler EJ, Duman RS: Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996, 16:2365-2372.
57. Smith MA, Makino S, Kvetnansky R, Post RM: Stress alters the expression of brain-dirived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995, 15:1768-1777.
58. Altar CA: Neurotrophins and depression. Trends Pharmacol Sci 1999, 20:59-61. A discussion of how current antidepressant treatments may work by increasing endogenous brain levels of brain-derived neurotrophic factor or neurotrophin-3, which in turn could promote monoamine-containing neurone growth and function.
59. Fleischhacker WW, Hinterhuber H, Bauer H, Pflug B, Bernan P, Simhandl C, Wilf R, Gerlach W, Jaklitsch H, Sastre-Y-Hernandez M et al.: A multicenter double-blind study of three different doses of the new cAMP phosphodiesrterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology 1992, 26:59-64.
60. Iona S, Cuomo M, Bushnik T, Naro F, Sette C, Hess M, Shelton ER, Conti M: Characterisation of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: Identification and differential expression of immunologically distinct forms in the rat brain. Mol Pharmacol 1998, 53:23-32.
61. Jin SL, Bushnik T, LAn L, Conti M: Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants dervived from the PDE4D gene. J Biol Chem 1998, 273:19672-19678.
62. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS: Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci 1999, 19:610-618. Expression of PDE4A and PDE4B, but not PDE4D, mRNA and immunore- activity were significantly increased in rat frontal cortex, and PDE4B in the nucleus accumbens, by chronic administration of sertraline, fluoxetine, desipramine, trancypromine, and electroconclusive seizure. In contrast, expression of PDE4 was unaffected by acute treatment or by non-antidepressant psychotropic drugs (e.g. cocaine, haloperidol).
63. Duman RS: Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998, 44:324-335.
64. Salzman SK: Mixed depression and anxiety - New concepts and therapeutic strategies. Drug Market Dev 1999, 10:20-24.
65. Williams M: Hope springs eternal: The importance of planning, serendipity and vision in clinical trial outcomes. Idrugs 1998, 1:887-889.